溶栓后紧急颅内支架置入的安全性:多中心匹配分析
该回顾性多中心研究基于26个卒中中心的前瞻性数据库,纳入大脑中动脉急性大血管闭塞合并颅内动脉粥样硬化性狭窄并接受救援支架置入的患者,按是否先行静脉溶栓分为两组并行倾向性评分匹配。匹配后52对患者分析显示,静脉溶栓/救援支架组与无静脉溶栓/救援支架组在症状性颅内出血(11.5% vs 9.6%;OR=1.2;95%CI 0.4-4.3;P=0.75)和90天死亡率(14.3% vs 11.7%;OR=1.3;95%CI 0.4-4.2;P=0.71)上均无显著差异,成功再通率和90天功能结局亦无显著差异。结论认为静脉溶栓未显著影响救援支架置入的安全性,也未改善再通和临床结局,需未来随机对照研究验证。
要点
- 匹配后52对患者中,静脉溶栓/救援支架组症状性颅内出血11.5%,无静脉溶栓/救援支架组9.6%,无显著差异。
- 90天死亡率静脉溶栓/救援支架组14.3%,无静脉溶栓/救援支架组11.7%,无显著差异。
- 实质血肿1型和2型、成功再通率及90天功能结局两组间均无显著差异。
核心结论
- 在颅内动脉粥样硬化性狭窄相关大脑中动脉大血管闭塞患者中,既往静脉溶栓未显著影响救援支架置入的安全性,也未改善再通率和临床结局;这些发现需谨慎解读,并需未来随机对照研究验证。
研究设计与样本
- 回顾性多中心研究,筛查欧洲、美国和中国26个卒中中心的前瞻性数据库,连续纳入接受救援支架置入的急性大脑中动脉颅内动脉粥样硬化性狭窄相关大血管闭塞患者,按是否先行静脉溶栓分为静脉溶栓/救援支架组和无静脉溶栓/救援支架组,采用倾向性评分匹配(协变量包括围手术期抗血小板治疗)估计静脉溶栓效应,匹配后52对患者纳入分析。
诊断标准与关键数值
- 主要安全结局为症状性颅内出血和90天死亡率;匹配后静脉溶栓/救援支架组 vs 无静脉溶栓/救援支架组:症状性颅内出血11.5% vs 9.6%(OR=1.2;95%CI 0.4-4.3;P=0.75),90天死亡率14.3% vs 11.7%(OR=1.3;95%CI 0.4-4.2;P=0.71);实质血肿1型和2型发生率、成功再通率及90天功能结局两组间均无显著差异。
临床应用与阅片要点
- 对于颅内动脉粥样硬化性狭窄相关大脑中动脉大血管闭塞接受救援支架置入的患者,既往静脉溶栓未显著增加症状性颅内出血和90天死亡率,也未改善再通和临床结局;作者指出这些发现需谨慎解读,并需未来随机对照研究验证。
局限性
- 原文结论指出这些发现应谨慎解读。
- 原文结论指出这些发现需通过未来随机对照研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: In patients with acute large vessel occlusion (LVO) of the MCA and underlying intracranial artery stenosis (ICAS), rescue stenting (RS) has been associated with better angiographic outcomes and higher rates of functional independence compared with mechanical thrombectomy (MT) alone. However, uncertainty exists regarding safety of RS in patients at higher risk for intracranial bleeding. The primary aim of this retrospective multicenter study was to compare safety outcomes between patients with acute ICAS-LVO of the MCA who underwent MT and RS with or without prior intravenous thrombolysis (IVT). Efficacy outcomes were assessed as a secondary aim.
MATERIALS AND METHODS: We screened the prospective databases of 26 stroke centers across Europe, the United States, and China for consecutive patients with acute MCA ICAS-LVO who received RS. Patients were divided into 2 groups based on prior administration of IVT: IVT/RS and no-IVT/RS. Propensity score matching (PSM), based on a set of covariates that also included periprocedural antiplatelet therapies, was used to estimate the effect of IVT treatment. Primary safety outcomes were the occurrence of symptomatic intracranial hemorrhage (sICH) and 90-day mortality.
RESULTS: After PSM, 52 pairs of patients were available for analysis. No significant differences were observed between the 2 groups regarding rates of sICH (11.5% in IVT/RS group versus 9.6% in no-IVT/RS group; OR = 1.2; 95% CI, 0.4-4.3; P = .75) and 90-day mortality (14.3% in the IVT/RS group versus 11.7% in the no-IVT/RS group; OR = 1.3; 95% CI, 0.4-4.2; P = .71). There were also no significant differences in the occurrence of parenchymal hemorrhage types 1 and 2, successful recanalization rates, and 90-day functional outcome.
CONCLUSIONS: The safety of RS in ICAS-LVO is not significantly affected by prior IVT administration. Furthermore, IVT does not result in improved recanalization and clinical outcome. These findings should be interpreted with caution and require validation through future randomized controlled studies.
引用
- Alexandre AM, Scarcia L, Consoli A, et al. Safety of Emergent Intracranial Stenting after Thrombolysis: A Multicenter Matched Analysis. AJNR Am J Neuroradiol. 2026. PMID: 40639974. doi:10.3174/ajnr.A8918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。